|
December 14, 2023
Adaptations and Type I Error Control in Platform Trials Ekkehard Glimm, PhD, Novartis Pharma, Switzerland
November 30, 2023
Our Most Important Discovery: the Question Scott Evans, PhD, George Washington University
November 02, 2023
Innovative Design and Analysis Approaches for Master Protocols James Wason, PhD, Newcastle University
September 14, 2023
A Gate Group Sequential Design for Seamless Phase II/III Trial with Subpopulatrion Selection Jason Liao, PhD, Incyte Corporation
July 10, 2023
A Bayesian Machine Learning Approach for Estimating Heterogeneous Survivor Causal Effects: Applications to a Critical Care Trial Fan Li, PhD, Yale University
May 18, 2023
Introducing a lightweight version of R Markdown Yihui Xie, PhD, Posit Software, PBC (formerly known as RStudio)
April 6, 2023
Partially-global Frechet regression and its variable selection Yichao Wu, PhD, University of Illinois at Chicago
March 9, 2023
On the treatment effect estimation of count or recurrent event data Tu Xu, PhD, Vertex Pharmaceutical
February 16, 2023
Deep Neural Networks Guided Ensemble Learning for Point Estimation Tianyu Zhan, PhD, AbbVie Inc
|